预约演示
更新于：2025-07-15
Docetaxel
多西他赛
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C43H55NO15 |
InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N |
CAS号148408-66-6 |
关联
2,671
项与 多西他赛 相关的临床试验JPRN-UMIN000021079
Upfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancer - UFAD in mHNPC
NCT06348134
Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer
NCT05296005
Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial
100 项与 多西他赛 相关的临床结果
登录后查看更多信息
100 项与 多西他赛 相关的转化医学
登录后查看更多信息
100 项与 多西他赛 相关的专利（医药）
登录后查看更多信息
31,237
项与 多西他赛 相关的文献（医药）2025-12-31INTERNATIONAL JOURNAL OF HYPERTHERMIA
Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching
Article
作者: Yu, Yang ; Fu, Yu-Bin ; Ma, Ru ; Yang, Rui ; Li, Yan ; Wei, Tian ; Li, Bing ; Su, Yan-Dong
OBJECTIVE:
Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM).
METHODS:
PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens.
RESULTS:
After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005).
CONCLUSIONS:
Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment.
2025-12-31Human Vaccines & Immunotherapeutics
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
Article
作者: You, Shuhui ; Gong, Caifeng ; Cai, Qi ; Huang, Jinglong ; Zhang, Wen ; Zhou, Aiping
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought to assess the cost-effectiveness of T-DXd in both the United States (US) and Chinese healthcare systems. Markov models were developed to evaluate the overall cost, incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and life years (LYs) of treatment with T-DXd compared with docetaxel, nivolumab, and pyrotinib for patients in the US and China. The level of willingness-to-pay (WTP) in the US and China is 150,000/QALYs and 32,517/QALYs, respectively. Sensitivity analyses were carried out to ensure the precision of the model. T-DXd yielded additional QALYs of 0.63 and 0.06 with an ICER of $338997.84 and $1437258.33 per QALY, respectively, in the US compared to the docetaxel and nivolumab regimens. And T-DXd yielded additional QALYs of 0.63, 0.06, and 0.13 with an ICER of $137959.45, $623805.93, and $515447.12 per QALY, respectively, in China compared to the docetaxel, nivolumab, and pyrotinib regimens. Sensitivity analysis showed that the cost of drugs is the most influential factor. T-DXd provides substantial therapeutic benefit for NSCLC patients with HER2 mutations who have had previous treatment but is not deemed cost-effective in either the US or China when compared to docetaxel, nivolumab, and pyrotinib. Price reduction is perhaps the main way to make T-DXd cost-effective.
2025-12-01Journal of Gastrointestinal Cancer
Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence
Article
作者: Yamamoto, Shun ; Honma, Yoshitaka ; Kato, Ken ; Igaue, Shota ; Daiko, Hiroyuki ; Ishiyama, Koshiro ; Kurita, Daisuke ; Shiraishi, Kazuhiro ; Itoyama, Mai ; Yokoyama, Kazuki ; Imazeki, Hiroshi ; Oguma, Junya ; Kashihara, Tairo
BACKGROUND:
Docetaxel-cisplatin-5-fluorouracil (DCF) is a new standard neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. However, some patients experience recurrence and require further systemic platinum-containing chemotherapy. It is unclear whether such regimens are appropriate after a poor histopathological response to neoadjuvant DCF.
METHODS:
Data were retrospectively collected on patients with recurrence of ESCC treated with palliative chemotherapy after neoadjuvant DCF at our institution between February 2014 and June 2022. We defined patients with a grade 0-1 histopathological response as insufficient responders (IRs) and those with grade 2-3 as good responders (GRs). The correlation between the histopathological response and the response to palliative chemotherapy was investigated.
RESULTS:
Thirty-two patients (median age 63.5 years, range 46-76) were included. Performance status was 0 in 12 (37.5%), 1 in 16 (50.0%), and 2 in 4 (12.5%). Histopathological response grades 0/1/2/3 were 3.1%/68.7%/21.9%/6.3%, respectively. Platinum-containing chemotherapy was administered to 13 patients (56.5%) in the IR group and 9 (100%) in the GR group. The overall response rate was 34.8%, and median progression-free survival was 2.431 months in the IR group and 44.4% and 4.041 months, respectively, in the GR group. Multivariate analysis identified a chemotherapy-free interval of < 6 months as an independent prognostic factor (HR 4.096, 95% CI 1.116-15.037) but not the histopathological response (HR 1.137, 95% CI 0.309-4.177).
CONCLUSIONS:
Histopathological response to neoadjuvant DCF therapy did not affect the efficacy of first-line chemotherapy for recurrent ESCC.
2,220
项与 多西他赛 相关的新闻（医药）2025-07-15
·动脉网
申请上市突破性疗法临床研究医药出海
2025-07-14
临床2期临床3期引进/卖出临床结果临床失败
2025-07-13
·信狐药迅
100 项与 多西他赛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早期乳腺癌 | 欧盟 | 2012-05-22 | |
| 早期乳腺癌 | 冰岛 | 2012-05-22 | |
| 早期乳腺癌 | 列支敦士登 | 2012-05-22 | |
| 早期乳腺癌 | 挪威 | 2012-05-22 | |
| 胃食管交界处腺癌 | 欧盟 | 2012-05-22 | |
| 胃食管交界处腺癌 | 冰岛 | 2012-05-22 | |
| 胃食管交界处腺癌 | 列支敦士登 | 2012-05-22 | |
| 胃食管交界处腺癌 | 挪威 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 欧盟 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 欧盟 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 冰岛 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 冰岛 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 列支敦士登 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 列支敦士登 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 挪威 | 2012-05-22 | |
| 转移性去势抵抗性前列腺癌 | 挪威 | 2012-05-22 | |
| 转移性胃腺癌 | 欧盟 | 2012-05-22 | |
| 转移性胃腺癌 | 冰岛 | 2012-05-22 | |
| 转移性胃腺癌 | 列支敦士登 | 2012-05-22 | |
| 转移性胃腺癌 | 挪威 | 2012-05-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 去势敏感前列腺癌 | 临床3期 | 英国 | 2024-06-11 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-06-08 | |
| 激素依赖性前列腺癌 | 临床3期 | 奥地利 | 2023-05-16 | |
| 激素依赖性前列腺癌 | 临床3期 | 德国 | 2023-05-16 | |
| 晚期恶性实体瘤 | 临床3期 | 印度 | 2021-04-29 | |
| 实体瘤 | 临床3期 | 印度 | 2021-04-29 | |
| 循环肿瘤细胞 | 临床3期 | 英国 | 2017-01-11 | |
| 转移性前列腺癌 | 临床3期 | 英国 | 2017-01-11 | |
| HER2阳性乳腺癌 | 临床3期 | 美国 | 2016-03-14 | |
| HER2阳性乳腺癌 | 临床3期 | 中国 | 2016-03-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 憲淵醖襯網顧遞壓憲艱(廠鑰觸鬱糧壓願範淵襯) = 糧願餘齋夢鏇醖鹽願齋 醖壓衊膚鏇範蓋蓋積構 (糧鹹築鑰壓壓衊蓋築窪 ) 更多 | 积极 | 2025-07-03 | |||
临床3期 | 局限性前列腺癌 辅助 | 350 | Docetaxel + Standard of Care (RT+ADT) | 憲鬱鏇遞鹽憲膚淵積鑰(蓋鹽鹽壓選網範製顧遞) = 鏇願鬱襯糧範獵鹹觸鹹 鬱構簾鬱積觸餘糧窪餘 (壓衊壓鏇壓糧廠餘築顧 ) | 积极 | 2025-05-30 | |
(Standard of Care (RT+ADT)) | 憲鬱鏇遞鹽憲膚淵積鑰(蓋鹽鹽壓選網範製顧遞) = 齋襯淵衊襯構齋蓋夢膚 鬱構簾鬱積觸餘糧窪餘 (壓衊壓鏇壓糧廠餘築顧 ) | ||||||
临床2/3期 | 头颈部肿瘤 cisplatin-ineligible | 356 | Concurrent Docetaxel + Radiation Therapy | 糧繭襯範製襯積憲築鏇(構選夢鏇衊願艱壓糧顧) = 鹽襯衊選簾顧醖夢壓網 憲壓鏇網築獵範簾膚範 (鹹襯艱鏇積鏇鏇獵淵鬱, 29.9 ~ 44.1) 更多 | 积极 | 2025-05-30 | |
Radiation Therapy Alone | 糧繭襯範製襯積憲築鏇(構選夢鏇衊願艱壓糧顧) = 積憲膚網遞廠醖獵蓋鹽 憲壓鏇網築獵範簾膚範 (鹹襯艱鏇積鏇鏇獵淵鬱, 17.7 ~ 30.3) 更多 | ||||||
N/A | 前列腺癌 prostate-specific antigen | - | 醖觸觸夢壓觸鏇遞繭廠(窪鬱繭淵襯築憲顧選窪): HR = 1.52 (95% CI, 0.87 ~ 2.68), P-Value = 0.14 更多 | 不佳 | 2025-05-30 | ||
临床1期 | - | 6 | 繭構繭鹹積築網淵觸選(積餘鏇製糧壓壓積淵廠) = No BH011-related serious adverse events (AEs) occurred 選鏇淵蓋衊蓋醖艱構顧 (築淵夢鑰衊遞積糧鑰鹽 ) 更多 | 积极 | 2025-05-30 | ||
N/A | - | Doxorubicin/cyclophosphamide combined with paclitaxel (ACT) | 衊餘築遞糧夢齋簾壓簾(觸獵獵網艱襯糧鬱網選) = 壓遞蓋壓衊網獵膚鹽廠 積築夢築積範遞築齋廠 (簾鏇鏇鏇獵蓋鑰襯淵範 ) 更多 | 不佳 | 2025-05-30 | ||
Docetaxel/cyclophosphamide (TC) | 衊餘築遞糧夢齋簾壓簾(觸獵獵網艱襯糧鬱網選) = 廠鑰網糧衊範夢淵選蓋 積築夢築積範遞築齋廠 (簾鏇鏇鏇獵蓋鑰襯淵範 ) 更多 | ||||||
N/A | - | 696 | Early Docetaxel Therapy | 廠醖繭膚範衊顧製憲齋(築壓餘艱鹹觸製糧鑰壓) = 願顧鏇簾鑰齋窪願顧夢 艱簾積鬱觸網製艱餘憲 (遞廠願憲積糧憲鏇廠糧 ) 更多 | 积极 | 2025-05-30 | |
Delayed Docetaxel Therapy | 廠醖繭膚範衊顧製憲齋(築壓餘艱鹹觸製糧鑰壓) = 淵鏇糧糧糧簾鹽膚餘醖 艱簾積鬱觸網製艱餘憲 (遞廠願憲積糧憲鏇廠糧 ) 更多 | ||||||
N/A | 转移性前列腺癌 PTEN inactivation | Decipher score | 832 | 醖醖膚窪獵選觸廠積鹽(顧齋鹹繭簾築壓壓觸簾): HR = 0.57 (95% CI, 0.42 ~ 0.76), P-Value = 0.002 | 积极 | 2025-05-30 | ||
N/A | 子宫平滑肌肉瘤 辅助 | 76 | 鬱餘廠鑰顧衊糧糧壓製(鏇糧齋積製鬱餘餘顧鏇) = Treatment with D was associated with improved PFS for metastatic ULMS compared to treatment with GT 餘遞範遞遞壓鏇膚繭鏇 (夢襯壓範餘觸艱積壓鹹 ) | 积极 | 2025-05-30 | ||
临床1/2期 | 25 | 廠築艱繭構遞鬱鏇獵餘(獵顧淵窪鏇襯糧糧襯壓) = 範襯蓋鹹獵窪蓋廠廠襯 構範繭衊觸壓蓋壓獵艱 (餘願選網鹹範觸觸網選 ) 更多 | 积极 | 2025-05-30 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用